Associations - Breyanzi (lisocabtagene maraleucel)

No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1
MYC rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Lymphoma	MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Lymphoma	lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria lisocabtagene maraleucel Sensitive : C2	lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria lisocabtagene maraleucel Sensitive : C2
MYC rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria lisocabtagene maraleucel Sensitive : C2	lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria lisocabtagene maraleucel Sensitive : C2
BCL6 rearrangement	Diffuse Large B Cell Lymphoma	BCL6 rearrangement	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria lisocabtagene maraleucel Sensitive : C2	lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria lisocabtagene maraleucel Sensitive : C2
MYC rearrangement + BCL2 rearrangement	Lymphoma	MYC rearrangement + BCL2 rearrangement	Lymphoma	lisocabtagene maraleucel Sensitive: C3 – Early Trials lisocabtagene maraleucel Sensitive : C3	lisocabtagene maraleucel Sensitive: C3 – Early Trials lisocabtagene maraleucel Sensitive : C3
TMB-H	Lymphoma	TMB-H	Lymphoma	lisocabtagene maraleucel Sensitive: C3 – Early Trials lisocabtagene maraleucel Sensitive : C3	lisocabtagene maraleucel Sensitive: C3 – Early Trials lisocabtagene maraleucel Sensitive : C3
MYC overexpression	Mediastinal B Cell Lymphoma	MYC overexpression	Mediastinal B Cell Lymphoma	lisocabtagene maraleucel Resistant: C3 – Early Trials lisocabtagene maraleucel Resistant : C3	lisocabtagene maraleucel Resistant: C3 – Early Trials lisocabtagene maraleucel Resistant : C3
EZH2 overexpression	Mediastinal B Cell Lymphoma	EZH2 overexpression	Mediastinal B Cell Lymphoma	lisocabtagene maraleucel Resistant: C3 – Early Trials lisocabtagene maraleucel Resistant : C3	lisocabtagene maraleucel Resistant: C3 – Early Trials lisocabtagene maraleucel Resistant : C3
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	ibrutinib + lisocabtagene maraleucel Sensitive: C3 – Early Trials ibrutinib + lisocabtagene maraleucel Sensitive : C3	ibrutinib + lisocabtagene maraleucel Sensitive: C3 – Early Trials ibrutinib + lisocabtagene maraleucel Sensitive : C3
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	ibrutinib + lisocabtagene maraleucel Sensitive: C3 – Early Trials ibrutinib + lisocabtagene maraleucel Sensitive : C3	ibrutinib + lisocabtagene maraleucel Sensitive: C3 – Early Trials ibrutinib + lisocabtagene maraleucel Sensitive : C3
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	ibrutinib + lisocabtagene maraleucel Sensitive: C3 – Early Trials ibrutinib + lisocabtagene maraleucel Sensitive : C3	ibrutinib + lisocabtagene maraleucel Sensitive: C3 – Early Trials ibrutinib + lisocabtagene maraleucel Sensitive : C3
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	ibrutinib + lisocabtagene maraleucel Sensitive: C3 – Early Trials ibrutinib + lisocabtagene maraleucel Sensitive : C3	ibrutinib + lisocabtagene maraleucel Sensitive: C3 – Early Trials ibrutinib + lisocabtagene maraleucel Sensitive : C3
TP53 mutation	Diffuse Large B Cell Lymphoma	TP53 mutation	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Resistant: C3 – Early Trials lisocabtagene maraleucel Resistant : C3	lisocabtagene maraleucel Resistant: C3 – Early Trials lisocabtagene maraleucel Resistant : C3
TP53 mutation	Mantle Cell Lymphoma	TP53 mutation	Mantle Cell Lymphoma	lisocabtagene maraleucel Sensitive: C3 – Early Trials lisocabtagene maraleucel Sensitive : C3	lisocabtagene maraleucel Sensitive: C3 – Early Trials lisocabtagene maraleucel Sensitive : C3

Breyanzi (lisocabtagene maraleucel)

Associations
(23)

Associations
(23)

Breyanzi (lisocabtagene maraleucel)

Associations(23)

Associations(23)

Associations
(23)

Associations
(23)